AbbVie has submitted an application to the FDA for approval of SKYRIZI (risankizumab-rzaa) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. This follows positive Phase 3 AFFIRM study results demonstrating efficacy and safety. If approved, patients will have the option to start treatment with either subcutaneous injections or intravenous infusions, continuing maintenance with subcutaneous dosing every eight weeks. This new option aims to improve convenience and treatment flexibility for Crohn's disease patients, a chronic inflammatory condition affecting about 1 million Americans.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
